Jim Simons's position in NeuBase Therapeutics is currently worth $23.4 Thousand. That's 0.00% of their equity portfolio (3255th largest holding). The investor owns 1.44% of the outstanding NeuBase Therapeutics stock. The first NeuBase Therapeutics trade was made in Q3 2019. Since then Jim Simons bought shares nine more times and sold shares on eight occasions. The investor's estimated purchase price is $41.6 Thousand, resulting in a loss of 44%.